Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of mild or moderate Alzheimer's disease (stage 4 or 5).
- Your score on a memory test (MMSE) is between 12 and 22 at the screening visit.
- You have a caregiver who spends at least 10 hours per week with you and can come to all study visits.
- If you take Alzheimer's medications (donepezil, rivastigmine, galantamine, or memantine), the dose has been stable for at least 12 weeks.
- You do not have serious health problems like liver disease, kidney problems, uncontrolled high blood pressure, or a history of other mental health conditions such as major depression or bipolar disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.